2018
DOI: 10.6004/jnccn.2018.0007
|View full text |Cite
|
Sign up to set email alerts
|

NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018

Abstract: Natural killer (NK)/T-cell lymphomas are a rare and distinct subtype of non-Hodgkin's lymphomas. NK/T-cell lymphomas are predominantly extranodal and most of these are nasal type, often localized to the upper aerodigestive tract. Because extranodal NK/T-cell lymphomas (ENKL) are rare malignancies, randomized trials comparing different regimens have not been conducted to date and standard therapy has not yet been established for these patients. These NCCN Guidelines Insights discuss the recommendations for the … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
41
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 54 publications
(42 citation statements)
references
References 49 publications
1
41
0
Order By: Relevance
“…Currently, the National Comprehensive Cancer Network guideline recommends the evaluation of EBER1 ISH in BM when the specimen is morphologically negative for involvement of ENKL, and patients with one or more EBER1‐positive cells in BM specimen are thought to have advanced‐stage disease.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Currently, the National Comprehensive Cancer Network guideline recommends the evaluation of EBER1 ISH in BM when the specimen is morphologically negative for involvement of ENKL, and patients with one or more EBER1‐positive cells in BM specimen are thought to have advanced‐stage disease.…”
Section: Discussionmentioning
confidence: 99%
“…13,14 On the other hand, the current standard-of-care in advanced-stage ENKL is induction therapy with an intensive L-asparaginase-containing regimen, such as dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) therapy, followed by consolidative therapy with hematopoietic stem cell transplantation; the 5-year OS and PFS are 47% and 39%, respectively. 15,16 Currently, the National Comprehensive Cancer Network guideline recommends the evaluation of EBER1 ISH in © 2019 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd Table 2 Correlation between the total number of EBER1-positive cells in each bone marrow specimen and age, sex, or disease BM when the specimen is morphologically negative for involvement of ENKL, 10 and patients with one or more EBER1-positive cells in BM specimen are thought to have advanced-stage disease.…”
Section: Discussionmentioning
confidence: 99%
“…After being validated in the most common cancer subtypes, some of these approaches are now being tested in rare neoplasms such as T cell lymphoma (TCL) and leukemia (T-ALL). The need for effective and safe new therapies is urgent, as the overall prognosis for these rare diseases is generally poor (5, 6). …”
Section: Introductionmentioning
confidence: 99%
“…Overall, TCL represent about 10% of all non-Hodgkin’s lymphomas (NHL) (7). PTCL-not otherwise specified (PTCL-NOS) is the most common subtype (26%), followed by angioimmunoblastic TCL (AITL, 19%), anaplastic large cell lymphoma (ALCL) divided into anaplastic lymphoma kinase (ALK) positive (7%), and ALK negative (6%) and enteropathy-associated TCL (EATL; <5%) (5, 8). The majority of PTCL originate from the CD4+ helper cells while only a minority of PTCL is derived from the CD8+ cytotoxic cells.…”
Section: Introductionmentioning
confidence: 99%
“…Recently published national and international treatment guidelines are used to inform treatment selection on the basis of patients' clinical condition and tumor stage [7,[11][12][13][14]. Many topical and systemic therapies have been developed in recent decades.…”
Section: Current Therapeutic Options For Pctclmentioning
confidence: 99%